Disappointing the markets is becoming a habit

04/02/26 -"Even though the Q4 performance ensured that Novo delivered on the lowered 2025 expectations, the markets seem frustrated with the 2026 outlook, impacted by pricing and competitive pressures. After a ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

04/02/26

Download

You may also be interested by these reports :

16/02/26

Sandoz

While we have raised our target price, the upside in Sandoz remains limited. Sandoz’s shares are valued at a massive premium to most of its listed ...

13/02/26

NOVO NORDISK

What is Novo really up against?

12/02/26

Ipsen

Ipsen concluded 2025 with sales and profitability exceeding expectations, driven by growth across all therapeutic areas. The 2026 guidance surpassed ...

12/02/26

Novo Nordisk

Since the beginning of 2025, and even after the new CEO (Maziar Mike Doustdar) was appointed in August 2025, Novo has downgraded growth expectations ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue